secwatch.observer — SEC 8-K summary
======================================

Issuer:     Crinetics Pharmaceuticals, Inc. (CRNX)
CIK:        0001658247
Form:       8-K
Filed at:   2025-01-10T23:59:59+00:00
Accession:  0000950170-25-003801
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Crinetics' atumelnant Phase 2 CAH trial meets primary endpoint with up to 80% mean A4 reduction
--------------------------------------------------------------------------------

- Atumelnant reduced androstenedione up to 80% (120mg, p<0.0001); 80mg dose reduced by 774 ng/dL (p<0.0001).
- Normalized testosterone in 8/13 females; 6 of 11 impacted participants resumed menses during the 12-week study.
- Total adrenal volume consistently reduced across all dose cohorts; polycythemia resolved in 5 of 6 impacted participants.
- No treatment-related severe or serious AEs; no dose reductions or discontinuations; most common AEs were headache (7/28) and fatigue (5/28).
- Crinetics plans to initiate a global Phase 3 pivotal trial in adults and a Phase 2b/3 pediatric study in 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1658247/000095017025003801/0000950170-25-003801-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1658247/000095017025003801/crnx-20250110.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-003801

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer